Partnership Opportunities

According to a recent study by Beacon Targeted Therapies, one third of all disclosed preclinical or clinical gene therapy programs are in neurology, which encompasses more prevalent diseases like Parkinson's as well as rarer conditions like ALS and Huntington's. Attendees at the 3^rd Gene Therapy for Neurological Disorders meeting are seeking:

• Neurological biomarker technology
• Preclinical models of neurological disorders including Parkinson’s, Alzheimer’s, epilepsy and neuropathic pain
• Preclinical CRO services with CNS expertise
• Clinical CRO services with gene therapy expertise